Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Treanda | Bendamustine hydrochloride | Non-Hodgkin Lymphoma and Mantle Cell Lymphoma | Reimburse | Complete | ||
| Welireg | belzutifan | von Hippel-Lindau disease-associated tumours | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rezurock | belumosudil | Graft-versus-host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Beleodaq | Belinostat | Withdrawn | ||||
| Benlysta | Belimumab | systemic lupus erythematosus | Do not reimburse | Complete | ||
| Benlysta | Belimumab | Systemic lupus erythematosus | Do not list | Complete | ||
| Benlysta | belimumab | Lupus nephritis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Olumiant | baricitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | ||
| Olumiant | baricitinib | Alopecia areata, severe | Active | |||
| Xofluza | baloxavir marboxil | Influenza | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer |
Last Updated : May 14, 2024